Overview

Phase Ib Clinical Study of HDM1005 Injection

Status:
COMPLETED
Trial end date:
2025-02-14
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation study in overweight or obese subjects to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HDM1005 injection in overweight or obese subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.